Skip to content. | Skip to navigation

European Coalition on Homeopathic & Anthroposophic Medicinal Products

Navigation

New publication demonstrates negligible material risks of homeopathic medicinal products

23 Jul 2020

The findings of recent reviews of controlled homeopathic clinical trials were identified and matched with experimental data from toxicological studies in order to clarify what is known and not known about the material risks of homeopathic medicines.

Rules for toxicological risk assessment and management need to be applied independently of individual attitudes towards specific therapeutic options. European regulatory bodies have developed special protocols and decision trees to assure the safety of non-individualized homeopathic remedies. This narrative review leads to suggestions that could ease and improve toxicological decision making.

No homeopathy-specific type or pattern of side effects could be extracted from the meta-analysis data. No differences in the frequency of adverse reactions between homeopathic treatment and placebo treatment could be seen, no matter whether adverse events were reported in a quantitative or a qualitative manner. Some patterns of side effects show that adverse reactions do not necessarily correlate with treatment but with the condition of the patient.

Overall, the controlled clinical data available for the material risk assessment of homeopathic remedies support the statement that, if a risk exists, it must be so small that it has not yet been established.

For further information
  • Material Risks of Homeopathic Medicinal Products: Regulatory Frameworks, Results of Preclinical Toxicology, and Clinical Meta-Analyses and Their Implications, Habs, Koller, Complementary Medicine Research, DOI: 10.1159/000507952, July 2020
News from ECHAMP

Subscribe here to receive regular information on developments affecting homeopathic and anthroposophic medicinal products in the EU.